Christopher J Molloy

List of Publications by Year
in descending order

42 papers	2,363 citations	304602 22 h-index	289141 40 g-index
42 all docs	42 docs citations	42 times ranked	2116 citing authors

#	Article	IF	Citations
1	Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6363-6369.	1.0	3
2	Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5303-5307.	1.0	7
3	Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141). Journal of Medicinal Chemistry, 2011, 54, 7860-7883.	2.9	30
4	The discovery of novel cyclohexylamide CCR2 antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7496-7501.	1.0	10
5	Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3925-3929.	1.0	11
6	Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEGâ€TPOm) After Single Intravenous Dose Administration in Healthy Subjects. Journal of Clinical Pharmacology, 2009, 49, 336-350.	1.0	30
7	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Molecular Cancer Therapeutics, 2009, 8, 3151-3161.	1.9	103
8	Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1642-1648.	1.0	40
9	Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1603-1606.	1.0	15
10	Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2097-2102.	1.0	46
11	Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1926-1930.	1.0	30
12	Structure-based optimization of a potent class of arylamide FMS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3632-3637.	1.0	29
13	Pharmacodynamics and Pharmacokinetics of the Novel Thrombopoietin Mimetic Peptide RWJ-800088 in Humans. Clinical Pharmacology and Therapeutics, 2008, 84, 481-487.	2.3	18
14	Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Molecular Cancer Therapeutics, 2006, 5, 160-169.	1.9	175
15	A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2200-2204.	1.0	15
16	A functional radioreceptor assay of alpha-V-beta-3 (Î±vÎ²3) inhibitors in plasma: Application as an ex vivo pharmacodynamic model. Journal of Proteomics, 2005, 65, 107-120.	2.4	1
17	Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells. Journal of Medicinal Chemistry, 2005, 48, 909-912.	2.9	436
18	Fighting pulmonary fibrosis: new science brings new therapeutic opportunities. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 361-368.	0.5	3

#	Article	IF	Citations
19	ROLE OF MATRIX METALLOPROTEINASES AND PLASMINOGEN ACTIVATORS IN CANCER INVASION AND METASTASIS: THERAPEUTIC STRATEGIES. , 2002, , 91-122.		10
20	Design and Synthesis of 4,5-Disubstituted-thiophene-2-amidines as Potent Urokinase Inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 491-495.	1.0	26
21	Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 915-918.	1.0	92
22	Structure-Based design, synthesis and sAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1379-1382.	1.0	15
23	Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1633-1638.	3.3	74
24	Novel cardiovascular actions of the activins. Journal of Endocrinology, 1999, 161, 179-185.	1.2	31
25	Activin A and TGF-Î² Stimulate Phosphorylation of Focal Adhesion Proteins and Cytoskeletal Reorganization in Rat Aortic Smooth Muscle Cells. Experimental Cell Research, 1999, 251, 194-202.	1.2	47
26	Orally Active Endothelin Receptor Antagonist BMS-182874 Suppresses Neointimal Development in Balloon-Injured Rat Carotid Arteries. Journal of Cardiovascular Pharmacology, 1995, 26, 908-915.	0.8	50
27	Uneven distribution of protein kinase C-? and -? isozymes in human sarcomas and carcinomas. Journal of Cellular Physiology, 1994, 159, 434-440.	2.0	5
28	Endothelin-1 and angiotensin-II stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signaling mechanisms. Molecular Endocrinology, 1994, 8, 148-158.	3.7	58
29	Novel signal transduction targets in cardiovascular disease: Role of platelet-derived growth factor in vascular smooth muscle cell proliferation. Drug Development Research, 1993, 29, 148-157.	1.4	3
30	Effects of thrombin receptor activating peptide on phosphoinositide hydrolysis and protein kinase C activation in cultured rat aortic smooth muscle cells: evidence for â€œtethered-ligandâ€•activation of smooth muscle cell thrombin receptors. Biochemical Pharmacology, 1993, 45, 1577-1582.	2.0	19
31	Altered expression of a mouse epidermal cytoskeletal protein is a sensitive marker for proliferation induced by tumor promoters. Carcinogenesis, 1992, 13, 963-968.	1.3	2
32	Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells. Peptides, 1992, 13, 499-508.	1.2	54
33	Development of a highly efficient expression cDNA cloning system: application to oncogene isolation.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5167-5171.	3.3	148
34	Expression of protein kinase C I in NIH 3T3 cells increases its growth response to specific activators. FEBS Letters, 1990, 260, 281-284.	1.3	16
35	EGF Triggers a Similar Signalling Cascade in Different Cell Types Overexpressing the EGF Receptor. , 1990, , 39-47.		1
36	PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature, 1989, 342, 711-714.	13.7	502

#	Article	IF	Citations
37	Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8063-8067.	3.3	98
38	Keratin polypeptide expression in mouse epidermis and cultured epidermal cells. Differentiation, 1988, 37, 86-97.	1.0	22
39	Effect of retinoid deficiency on keratin expression in mouse bladder. Experimental and Molecular Pathology, 1988, 49, 128-140.	0.9	34
40	Epidermal Growth Factor Activates Phosphoinositide Turnover and Protein Kinase C in BALB/MK Keratinocytes. Molecular Endocrinology, 1988, 2, 799-805.	3.7	34
41	Alterations in the expression of specific epidermal keratin markers in the hairless mouse by the topical application of the tumor promoters 2,3,7,8-tetrachlorodibenzo-p-dioxin and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis, 1987, 8, 1193-1199.	1.3	14
42	Alterations in Mouse Epidermal Keratin Production Induced by Dietary Vitamin A Deficiency. Annals of the New York Academy of Sciences, 1985, 455, 739-740.	1.8	6